ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01136733
Recruitment Status : Unknown
Verified August 2016 by Eisai Inc..
Recruitment status was:  Active, not recruiting
First Posted : June 3, 2010
Last Update Posted : September 23, 2016
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Actual Primary Completion Date : June 2014
  Estimated Study Completion Date : May 2017
  Certification/Extension First Submitted : April 18, 2016

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 November 23, 2016
January 19, 2017
2 February 7, 2019